Bayer AG (USD) Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.

Bayer AG (USD) Active

Kaiser-Wilhelm-Allee 1, Leverkusen, DE, 51368

Stock Price USD

Price Change

Last Dividend USD

C+

Latest Rating

BAYRY's stock peer is ALPMF (Astellas Pharma Inc.)

BAYRY's stock peer is ALPMY (Astellas Pharma Inc.)

BAYRY's stock peer is FSNUF (Fresenius SE & Co. KGaA)

BAYRY's stock peer is GIKLY (Grifols, S.A.)

BAYRY's stock peer is JDHIF (JD Health International Inc.)

BAYRY's stock peer is OTSKF (Otsuka Holdings Co., Ltd.)

BAYRY's stock peer is OTSKY (Otsuka Holdings Co., Ltd.)

BAYRY's stock peer is RYLPF (Koninklijke Philips N.V.)

BAYRY's stock peer is SDZNY (Sandoz Group AG)

Healthcare Drug Manufacturers - General

Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.

80%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

20%

Debt To Equity

20%

Price To Earnings

80%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2026-04-28	2026-05-11	0.03	0.30 %	Annual
2025-04-29	2025-05-12	0.03	0.47 %	Annual
2024-04-30	2024-05-13	0.03	0.40 %	Annual
2023-05-03	2023-05-15	0.66	4.18 %	Annual
2022-05-03	2022-05-16	0.53	3.33 %	Annual
2021-04-29	2021-05-10	0.60	3.71 %	Annual
2020-04-30	2020-05-14	0.76	4.56 %	Annual
2019-04-30	2019-05-13	0.78	7.14 %	Annual
2018-06-25	2018-07-02	0.42	4.24 %	Monthly
2018-05-29	2018-06-11	0.81	2.76 %	Annual
2017-05-03	2017-05-15	2.96	2.42 %	Annual
2016-04-29	2016-05-12	2.87	2.42 %	Annual
2015-05-27	2015-06-08	2.46	1.65 %	Annual
2014-04-29	2014-05-12	2.90	2.23 %	Annual
2013-04-26	2013-05-09	2.48	2.41 %	Annual
2012-04-27	2012-05-10	2.15	3.14 %	Annual
2011-04-29	2011-05-12	2.21	2.66 %	Annual
2010-04-30	2010-05-13	1.84	2.87 %	Annual
2009-05-12	2009-05-26	1.89	3.77 %	Annual
2008-04-25	2008-05-08	2.10	2.57 %	Annual
2007-04-27	2007-05-10	1.36	1.99 %	Annual
2006-04-28	2006-05-12	1.20	2.73 %	Annual
2005-04-29	2005-05-12	0.71	8.34 %	Semi-Annual
2005-01-27	2005-02-10	1.94	5.95 %	Semi-Annual
2004-04-30	2004-05-13	0.60	2.20 %	Annual
2003-04-25	2003-05-12	1.01	5.70 %	Annual
2002-04-26	2002-05-13	0.81	2.35 %	Annual
2001-04-27	2001-05-10	1.24	2.83 %	Annual
2000-04-28	2000-05-12	1.17	2.84 %	Annual
1999-04-30	1999-05-13	1.08	2.55 %	Annual
1998-05-05	1998-05-14	1.07	2.34 %	Annual
1997-04-30	1997-05-12	0.72	1.83 %	Annual
1996-04-25	1996-05-06	0.72	2.11 %	Annual
1995-04-26	1995-05-05	0.69	2.69 %	Annual

Recent News

Bayer Welcomes Kacy Perry as New Country Division Head for Crop Science Canada

CALGARY, Alberta--(BUSINESS WIRE)--The Crop Science division of Bayer announced that Kacy Perry has been appointed the Country Division Head (CDH) for Crop Science Canada, effective July 1. In this role, she will lead 550+ employees working at multiple sites across Canada and serves as a member of Bayer's North American Leadership Team for Crop Science. Perry currently serves as the North America Soybean Business Lead for Bayer's Crop Science division and has been with Bayer for the entirety of.

2026-06-18 15:22:00

Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth

BASEL, Switzerland & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further enhance speed of decision making. These changes reflect the company's commitment to continuously adapt and advance its Road to Billions strategy aimed at helping billions of people live healthier lives.

2026-06-08 08:00:00

Phase III FIND‑CKD Results Show Bayer's KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with non-diabetic chronic kidney disease (nd-CKD) who were also receiving background standard of care. In the trial, KERENDIA met the primary endpoint by showing a significant reduction in the rate of kidney disease progression, as measured by estimated glomerular filtration rate (eGFR) slope (mean annual change from baseline to month.

2026-06-05 06:40:00

ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial

WHIPPANY, N.J.--(BUSINESS WIRE)--Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with NUBEQA® (darolutamide; n=55) experienced significantly less decline in objective cognitive performance over 24 weeks compared with those treated with enzalutamide (n=56).

2026-05-30 17:24:00

Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and country superstar and five-time Entertainer of the Year Luke Bryan today launched their 2026 campaign to expand access to food and nutrition in rural America, with Bayer donating 1 million meals* through Feeding America®. The campaign kicks off May 14–16 in California with a Walmart community food drive in Clovis, followed by additional food collection at Farm Tour stops in Clovis and Elk Grove. In partnership with Central California Food Bank and Sacr.

2026-05-13 09:04:00

Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis

BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women's Hospital that evaluated the investigational PET/CT radiotracer I 124 evuzamitide.1,5 The study met the primary endpoints of sensitivity (the ability of a test to identify individuals who have the condition) and specificity (the ability of a test to identify individuals who do not have the condition) for the diagnosis of.

2026-05-07 02:30:00

Bayer and bp Form Strategic Alliance to Jointly Scale Camelina as Intermediate Crop for Biofuels

ST. LOUIS--(BUSINESS WIRE)--Bayer, a life science company, and bp, a global integrated energy company, today announced that they have entered into a long-term strategic alliance to jointly scale the crop camelina, under the brand name newgold®. The alliance will commercialize camelina starting in North America. bp brings expertise in fuels and refining, while Bayer will utilize its industry leading expertise in seed technology, as well as its extensive farmer customer base. The alliance aims to.

2026-05-06 08:00:00

Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

BERLIN & SAN FRANCISCO--(BUSINESS WIRE)--Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic R.

2026-05-06 02:30:00

Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that a broad set of data from its stroke franchise will be presented at the 2026 European Stroke Organisation Conference (ESOC), including new late-breaking analyses from its global, landmark Phase III OCEANIC-STROKE study of asundexian, an investigational oral Factor XIa inhibitor. In total, 13 abstracts will be presented, including four OCEANIC-STROKE sub-analyses. Additionally, Bayer will present nine real-world analyses examining stroke.

2026-04-29 08:00:00

Bayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural Class

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bayer Canada is proud to support the Simon Fraser University (SFU) School of Medicine - the first medical school in Western Canada in nearly 60 years. The new school is dedicated to help improve primary care and the critical shortage of family doctors in British Columbia, where approximately 800,000 residents lack access to a primary care physician. SFU is set to welcome its inaugural class of 48 students at an interim location on the SFU Surrey campus thi.

2026-04-15 16:33:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions